Osprey Medical today announced that it has received US FDA 510(k) clearance for its advanced DyeVert™ PLUS Contrast Reduction System. This new platform augments Osprey's current technology with the capability to actively manage dye administration during coronary interventions.
http://ospreymed.com/wp-content/uploads/2017/04/DyeVert-PLUS-System.jpg733813Rob Coleman/wp-content/uploads/2017/04/osprey-logo-224w.pngRob Coleman2017-03-09 01:40:312017-06-23 18:08:58Osprey Medical Receives US FDA Clearance for DyeVert™ Plus
Osprey Medical is pleased to announce the expansion of its portfolio with introduction of the DyeVert™ PLUS Contrast Modulation/Monitoring System. This new platform integrates the current DyeVert technology with substantial patient management and monitoring capabilities.
http://ospreymed.com/wp-content/uploads/2017/04/DyeVert-PLUS-System.jpg733813Rob Coleman/wp-content/uploads/2017/04/osprey-logo-224w.pngRob Coleman2016-11-02 01:17:002017-05-06 19:02:12Osprey Introduces DyeVert PLUS at TCT
Analyst Coverage Disclaimer
Please note that any opinions, esimates or forecasts regarding Osprey Medical's performance made by analysts mentioned on this website are theirs alone and do not represent opinions, forecasts or predictions of Osprey Medical or its management. Osprey Medical does not by its reference to any analysts imply its endorsement of or concurrence with their information, conclusions, or recommendations. Information provided by analysts is subject to change, and Osprey Medical cannot guarantee its accuracy.